Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Robert Armstrong, VP, Global External R&D at Eli Lilly is entrusted with perhaps the most challenging task in his organization - cherry-picking the best research partners to help enrich Lilly's pipeline of future drugs - yet keep costs on those multiple research projects as low as possible. Armstrong, who has struck many deals with Indian firms including a joint venture with Jubilant, advocates openness in communication with his partners, but said in an interview with PharmAsia News' India bureau that overcoming challenges and reaching targeted milestones is the true test for strong partnerships.
You may also be interested in...
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes